GlassScriptPhysician profile
Matthew Sirott
NPI 1023014461
$2,556.25
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,103 · 2020: $420 · 2021: $642 · 2022: $304 · 2023: $87.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $47.63 · Education: $39.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $47.63 |
| Education | $39.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $365.94 | 2019-2021 | |
| Amgen INC. | $327.75 | 2019-2022 | |
| Janssen Biotech, INC. | $265.20 | 2019-2023 | Imbruvica |
| Pfizer INC. | $171.14 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $126.80 | 2019-2023 | |
| Lilly USA, LLC | $125.92 | 2019-2021 | |
| Incyte Corporation | $118.19 | 2020-2021 | |
| Kite Pharma, INC. | $117.11 | 2019-2022 | |
| Seagen INC. | $114.26 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $92.30 | 2019-2020 | |
| Genzyme Corporation | $84.73 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $74.91 | 2019-2023 | Keytruda |
| Tersera Therapeutics LLC | $69.70 | 2019 | |
| Genentech USA, INC. | $66.78 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.21 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $53.82 | 2019-2020 | |
| Elekta, INC. | $40.49 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $31.35 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $29.93 | 2022 | |
| Dendreon Pharmaceuticals LLC | $26.79 | 2019 | |
| Tesaro, INC. | $25.85 | 2019 | |
| Clovis Oncology, INC. | $19.73 | 2019 | |
| Rigel Pharmaceuticals, INC. | $19.65 | 2020 | |
| Novocure INC. | $19.41 | 2019 | |
| Eisai INC. | $19.00 | 2019 | |
| Mylan Institutional INC. | $18.86 | 2019 | |
| Sun Pharmaceutical Industries INC. | $18.22 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.19 | 2020 | |
| Myovant Sciences INC. | $15.64 | 2021 | |
| Amag Pharmaceuticals, INC. | $13.68 | 2019 | |
| Daiichi Sankyo INC. | $11.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Sirott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.